Medical Devices

FDA De Novo Pathway Assessment Support

Last reviewed: 2026-11-08

Considering an FDA De Novo route? Start with why a predicate may not fit, the device risk profile and available evidence. Tell us the current regulatory discussion so a specialist can separate De Novo from 510(k) or PMA planning.

Discuss my FDA De Novo requirement

Novel medical device prototype with classification pathway sketch for FDA De Novo planning

At a glance

Is this for you?

Novel-device manufacturers where a suitable predicate may not exist and a risk-based De Novo classification could be relevant.

What to send with your enquiry

  • Device description
  • Indications
  • Design and risk information
  • Predicate search notes
  • Available studies and QMS status.

What a specialist can help with

  • Feasibility and pathway review
  • Risk-control and evidence-gap map
  • Potential Pre-Submission question planning
  • Testing and performance-evidence workstream coordination
  • Submission-project coordination with appropriate regulatory specialists
Scope and report acceptance. De Novo pathway assessment is coordinated with specialists; FDA decides whether to grant a request. Capability must be verified before treating this page as a live offer.
Role clarity. Enquiry support and specialist introductions. Testing, technical advice, certification and regulatory decisions remain with the responsible service providers and authorities.

A novel low- to moderate-risk device without an appropriate predicate may warrant assessment of the FDA De Novo pathway. The route cannot be chosen from a marketing label alone. ConformArc can discuss an introduction to a provider that coordinates a specialist review of intended use, technology, classification history, risks, proposed controls and the evidence needed to support a request.

A useful early deliverable is a pathway decision memo that compares plausible alternatives, identifies missing performance and safety data, and sets out a submission work plan. Depending on the device, work may include bench, software, biological, electrical, usability or clinical evidence. Regulatory specialists should verify current FDA guidance and submission requirements. FDA decides whether to grant a De Novo request; ConformArc does not promise classification or market access.

Frequently asked questions

Is De Novo a fallback for every failed 510(k)?

No; eligibility and evidence need their own assessment.

Sources / further reading

Requirements can change. Confirm the current route and applicable edition for the specific product before starting the project.

Discuss this requirement

Tell us the product or company requirement, target market, current stage and what your customer has asked for. We will review the initial details and reply about the next step. You can start without uploading confidential documents.

We use your details to respond to this enquiry. If a suitable external specialist could help, we will tell you who we propose to contact and ask before sharing your name, contact details or project information. The specialist may then contact you about this request. Read the Privacy Notice. See also how we choose providers.

Related options for FDA De Novo.

Add more details (optional)

We use your details to respond to this enquiry. If a suitable external specialist could help, we will tell you who we propose to contact and ask before sharing your name, contact details or project information. Please do not include passwords, confidential documents or sensitive personal information.